Hypercholesterolemia
Conditions
Keywords
hypercholesterolemia, non-alcoholic fatty liver disease(NAFLD), THR-β
Brief summary
The purpose of this study is to assess the efficacy and safety of HSK31679 tablets compared with placebo in reducing low-density lipoprotein cholesterol (LDL-C) and MRI-PDFF after 12 weeks of treatment in patients with hypercholesterolemia and non-alcoholic fatty liver disease (NAFLD).
Interventions
DRUGHSK31679 low dose
HSK31679 low dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
DRUGHSK31679 medium dose
HSK31679 medium dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
DRUGHSK31679 high dose
HSK31679 high dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
DRUGPlacebo
placebo ，QD，oral，Day1 to week 12
DRUGEzetimibe 10mg
Ezetimibe 10mg+placebo of HSK31679 ，QD，oral，Day1 to week 12
Sponsors
Haisco Pharmaceutical Group Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Must be willing to participate in the study and provide written informed consent. 2. Male or female aged 18 ≤ age \< 65 at the time of signing the informed consent. 3. At the time of screening, patients who had not received lipid-regulation therapy within 6 weeks had fasting LDL-C≥3.34mmol/L（130mg/dL）. 4. (BMI) ≥18kg/m2 and female subjects ≥45.0 kg and male subjects ≥50.0 kg. 5. During screening, fasting triglyceride (TG) \<5.65 mmol/L. 6. During screening,MRI-PDFF≥8%. 7. Weight changes≤5% in the 4 weeks prior to screening.
Exclusion criteria
1. Did not discontinue any lipid-regulating therapy or any drug or supplement that may affect lipid levels 6 weeks before randomization or is expected to do so during the study period. 2. Homozygous familial hypercholesterolemia (HoFH) was diagnosed by genetic or clinical criteria. 3. Dyslipidemia caused by other diseases or drugs, such as rheumatoid arthritis, nephrotic syndrome, Cushing's syndrome, hypothyroidism, renal failure, systemic lupus erythematosus, glycogen accumulation, myeloma, lipodystrophy, acute porphyria, polycystic ovarian syndrome, etc 4. Before screening, LDL-C plasma exchange was performed within 12 months. 5. In the past, PCSK9 inhibitors, Lomitapide and Mipomersen were used for treatment. 6. uncontrolled hypertension had systolic blood pressure ≥160mmHg and/or diastolic blood pressure ≥100mmHg at screening/baseline. 7. type 1 diabetes, or newly diagnosed type 2 diabetes within 1 month, or poorly controlled type 2 diabetes, or who could not maintain the same hypoglycemic regimen during the study. 8. Stroke or transient ischemic attack (TIA), acute coronary syndrome, stable angina attack, severe deep vein thrombosis, or pulmonary embolism occurred in the 12 months prior to screening. 9. Major surgery (including but not limited to: coronary or other revascularization, coronary artery bypass surgery, and transplantation) within 12 months prior to screening or planned during the study period. 10. Chronic systemic disease or history, including but not limited to 1. Have a serious cardiopulmonary disease or history,Neurological disease or history,Autoimmune disease,Chronic digestive disease or history 2. Have thyroid disease or symptomatic abnormalities in thyroid function tests (e.g., thyroid stimulating hormone (TSH) \< 1.0 x lower limit of normal (LLN) or \> 1.5 x upper limit of normal (ULN)) 3. History of malignancy (excluding cured basal cell carcinoma of the skin, carcinoma in situ, and papillary thyroid carcinoma) or history of antitumor therapy within 5 years prior to screening 4. Disease or medical history assessed by the investigator as likely to affect the study 11. Bariatric surgery within 12 months at the time of screening
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage change in LDL-C from baseline at 12 week; | Baseline and Week 12 | Percentage change in fasting low-density lipoprotein cholesterol (LDL-C) from baseline after 12 weeks of treatment; |
| Percentage change in MRI-PDFF from baseline at 12 week； | Baseline and Week 12 | Percentage change of MRI-PDFF(change in liver fat content by nuclear magnetic resonance - Proton Density Fat Fraction) from baseline after 12 weeks of treatment; |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients with LDL-C<3.34mmol/L（<130mg/dL） | Baseline and Week 12 | After 12 weeks of treatment, the proportion of patients with LDL-C\<3.34mmol/L（\<130mg/dL） |
| Percentage change of fasting TG from baseline; | Week2,4,8,12 | After 2, 4, 8, 12 weeks of treatment, Percentage change of fasting triglycerides (TG), from baseline; |
| Percentage change of fasting TC from baseline; | Week2,4,8,12 | After 2, 4, 8, 12 weeks of treatment, Percentage change of fasting total cholesterol (TC) from baseline; |
| Percentage change in fasting LDL-C from baseline; | Week2,4,8 | Percentage change in fasting low-density lipoprotein cholesterol (LDL-C) from baseline after 2, 4, and 8 weeks of treatment; |
| Percentage change in body weight from baseline | Baseline and Week 12 | Percentage change in body weight from baseline after 12 weeks of treatment. |
| AUC0-τ of HSK31679 (All subjects) | up to 2,4,7 weeks | — |
| Cmax of HSK31679 (All subjects) | up to 2,4,7 weeks | — |
| Percentage change of fasting HDL-C from baseline; | Week2,4,8,12 | After 2, 4, 8, 12 weeks of treatment, Percentage change of fasting high-density lipoprotein cholesterol (HDL-C) from baseline; |
| The proportion of patients with MRI-PDFF decreased by > 30% | Baseline and Week 12 | After 12 weeks of treatment, the proportion of patients with MRI-PDFF decreased by \> 30%; |
Countries
China
Outcome results
None listed